Open AccessEnsartinib (X-396) a novel drug for anaplastic lymphoma kinase-positive non-small cell lung cancer patients: we need smart trials to avoid wasting good bullets
Author(s) -
Gianluca Spitaleri,
Antonio Passaro,
Filippo de Marinis
Publication year - 2018
Publication title -
chinese clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.733
H-Index - 22
eISSN - 2304-3873
pISSN - 2304-3865
DOI - 10.21037/cco.2018.09.03
Subject(s) - anaplastic lymphoma kinase , medicine , lung cancer , lymphoma , anaplastic large cell lymphoma , oncology , wasting , cancer , large cell , kinase , drug , non small cell lung cancer (nsclc) , cancer research , pharmacology , adenocarcinoma , malignant pleural effusion , biology , a549 cell , microbiology and biotechnology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom